Zydus Cadila has received tentative approval from the United States Food & Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets (US RLD- Myrbetriq Extended-Release Tablets), 25 mg and 50 mg.
Mirabegron is selective beta 3-adrenoceptor agonist approved for the treatment of Overactive Bladder (OAB), a chronic condition of the lower urinary tract characterized by symptoms of urinary urgency, with or without urge incontinence. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
The group now has 259 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: